Initiation: Multiple shots on goal, only one has to score
Relmada has a full pipeline of four programmes that treat all segments of the pain spectrum. The current lead programme, LevoCap ER, which should enter Phase III within the next 12-18 months, is an extended release version of a powerful narcotic and could be used in a large variety of areas. d-Methadone, BuTab ER and MepiGel each have unique qualities that could differentiate them in a crowded pain market. We value Relmada at $601m or $11.56 per basic share.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.